September 10, 2013
Yoshiki Yui, Kyoto University Hospital’s Department of Cardiovascular Medicine The double-blind method ought to be employed for clinical trials if Japan is to recoup confidence shaken by the data manipulation scandal involving Novartis Pharma’s blockbuster antihypertensive Diovan (valsartan), said a...read more